Homoeopathic treatment in fibromyalgia syndrome in reproductive women

EFFICACY OF INDIVIDUALIZED HOMOEOPATHIC MEDICINES IN THE TREATMENT OF FIBROMYALGIA SYNDROME AMONG WOMEN OF REPRODUCTIVE AGE GROUP: A DOUBLE BLIND RANDOMIZED PLACEBO CONTROLLED TRIAL - NIL

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/11/077281

Enrollment

Registered

2024-11-25

Start date

Unknown

Completion date

Unknown

Last updated

2024-12-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: M797- Fibromyalgia

Interventions

Intervention1: individualized homoeopathic medicine: Intervention is planned as administering indicated homoeopathic medicines in centesimal potencies, as decided appropriate to the case or condition.

dosage and repetition depending upon the individual requirement of the cases. Duration of therapy 3 months. Control Intervention1: placebo: This arm will receive placebo, indistinguishable in appearan

dosage and repetition depending upon the individual requirement of the cases. Duration of therapy 3 months. Control Intervention2: Placebo: This arm will receive placebo, indistinguishable in appearan

dosage and repetition depending upon the individual requirement of the cases. Duration of therapy 3 months. Control Intervention3: placebo: This arm will receive placebo, indistinguishable in appearan

dosage and repetition depending upon the individual requirement of the cases. Duration of therapy 3 months.

Eligibility

Inclusion criteria

Inclusion criteria: Women of reproductive age provided who have set in menarche, does not set in menopause. Age between 15 to 49 years. Patients suffering from Fibromyalgia syndrome according to Fibromyalgia criteria 2016 revision of American College of Rheumatology. Patients who will provide written informed consent. Patients of all religions, all socioeconomic status.

Exclusion criteria

Exclusion criteria: Patient suffering from any terminal illness, life threatening condition or taking medication for any major systemic diseases. Chronic alcoholism and substance abuse. Pregnant and lactating mothers. Psychologically unstable patients or insane individuals.

Design outcomes

Primary

Measure	Time frame
To evaluate the effect of individualized homoeopathic medicines of women of reproductive age group having fibromyalgia syndrome through fibromyalgia impact questionnaire (FIQ)Timepoint: Assessment will be done at baseline and after three months.	—

Secondary

Measure	Time frame
To evaluate causal attribution of Clinical outcome at end of treatment of Fibromyalgia syndrome by using Modified Naranjo Criteria (MONARCH)Timepoint: at end of treatment (three months)	—

Countries

India

Contacts

Public ContactDr Purnendu Ash

MAHESH BHATTACHARYYA HOMOEOPATHIC MEDICAL COLLEGE AND HOSPITAL

purnendubhms29@gmail.com9051420436

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026